Equillium Inc (EQ) Sector
Health Care

(Current) $2.24
-0.05 (-2.18%) Open Price: 2.50


Equillium Inc. is a biotechnology company focused on developing novel therapies for autoimmune and inflammatory disorders. Headquartered in La Jolla, California, the company was founded in 2017 and has emerged as a player in the field of immunology. Equillium's primary focus is on modulating the immune system to address unmet medical needs, particularly in conditions where the immune response is dysregulated.


One of the key therapeutic candidates in Equillium's pipeline is Itolizumab, a monoclonal antibody that targets the immune system by inhibiting the activity of the CD6-ALCAM pathway. This pathway plays a crucial role in T-cell activation, and by modulating it, Equillium aims to regulate the immune response in conditions such as acute graft-versus-host disease (aGVHD), lupus nephritis, and uncontrolled asthma. The company has conducted clinical trials to evaluate the safety and efficacy of Itolizumab, showcasing its commitment to advancing treatment options for patients with autoimmune disorders.


The leadership team at Equillium includes individuals with extensive experience in the biopharmaceutical industry, contributing to the company's strategic direction and execution. The company's mission is centered on improving the lives of patients by developing innovative therapies that modulate the immune system in a targeted and controlled manner.


Equillium places a strong emphasis on translational medicine and leveraging insights from immunology research to develop targeted therapies. The company's approach involves identifying and addressing specific pathways involved in immune dysregulation, with the goal of providing more precise and effective treatments for patients.



(03/01/24) $2.50
(03/04/24) $2.29
(03/04/24) (Qty.)352,149
(03/01/24) $2.30
(03/01/24) $2.63
(11/12/23) $0.45
(02/25/24) $3.25
LetsEncrypt SSL Secure Stripe Payment Processing